M
Michelle Conan-Cibotti
Researcher at National Institutes of Health
Publications - 10
Citations - 1214
Michelle Conan-Cibotti is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Tolerability & Reactogenicity. The author has an hindex of 8, co-authored 8 publications receiving 920 citations.
Papers
More filters
Journal ArticleDOI
Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection
Rebecca M. Lynch,Eli Boritz,Emily E. Coates,Adam DeZure,Patrick J Madden,Pamela Costner,Mary E. Enama,Sarah H. Plummer,LaSonji A. Holman,Cynthia S. Hendel,Ingelise J. Gordon,Joseph P. Casazza,Michelle Conan-Cibotti,Stephen A. Migueles,Randall Tressler,Robert T. Bailer,Adrian B. McDermott,Sandeep Narpala,Sijy O'Dell,Gideon Wolf,Jeffrey D. Lifson,Brandie A. Freemire,Robert J. Gorelick,Janardan P. Pandey,Sarumathi Mohan,Nicolas Chomont,Rémi Fromentin,Tae-Wook Chun,Anthony S. Fauci,Richard M. Schwartz,Richard A. Koup,Daniel C. Douek,Zonghui Hu,Edmund V. Capparelli,Barney S. Graham,John R. Mascola,Julie E. Ledgerwood,Vrc Study Team +37 more
TL;DR: A single infusion of mAb VRC01 significantly decreased plasma viremia and preferentially suppressed neutralization-sensitive virus strains, demonstrating the virological effect of this neutralizing antibody and highlighting the need for combination strategies to maintain virus suppression.
Journal ArticleDOI
Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
Martin R. Gaudinski,Katherine V. Houser,Kaitlyn M. Morabito,Zonghui Hu,Galina Yamshchikov,Ro Shauna S Rothwell,Nina M. Berkowitz,Floreliz Mendoza,Jamie G. Saunders,Laura Novik,Cynthia S. Hendel,LaSonji A. Holman,Ingelise J. Gordon,Josephine H. Cox,Srilatha Edupuganti,Monica A. McArthur,Nadine Rouphael,Kirsten E. Lyke,Ginny E. Cummings,Sandra Sitar,Robert T. Bailer,Bryant M. Foreman,Katherine E. Burgomaster,Rebecca S. Pelc,David N. Gordon,Christina R. DeMaso,Kimberly A. Dowd,Carolyn M. Laurencot,Richard M. Schwartz,John R. Mascola,Barney S. Graham,Theodore C. Pierson,Julie E. Ledgerwood,Grace L. Chen,Sarah H. Plummer,Pamela Costner,Kathryn Zephir,Joseph P. Casazza,Abidemi Ola,Milalynn Victorino,Carol Levinson,William Whalen,Xiaolin Wang,Jennifer Cunningham,Olga Vasilenko,Maria Burgos Florez,Somia P. Hickman,Iris Pittman,Lam Le,Brenda Larkin,Charla A. Andrews,Preeti Apte,Renunda Hicks,Cora Trelles Cartagena,Pernell Williams,Catina R. Boyd,Michelle Conan-Cibotti,Judy Stein,Florence Kaltovich,Hope DeCederfelt,Stacey McAdams,Phyllis Renehan,Wilbur Chen,Nancy Greenberg,Nancy Wymer,Linda Wadsworth,Melissa Billington,Toni Robinson,Colleen Boyce,Faith Pa'ahana Brown,Lisa Chrisley,Alyson Kwon,Prashant Patel,Panagoita Kominou,Brenda Dorsey,Staci Eddington,Shinyi Telscher,Myoughee Lee,Regina Mosely,April Ross,Geoffrey Ford,Briyana Domjahn,Jianguo Xu,Allison Beck,Rebecca Fineman,Shiela Heeke,Jean Winter,Shashi Nagar,Colleen F. Kelley,Mark J. Mulligan +89 more
TL;DR: Both DNA vaccines expressing premembrane and envelope Zika virus structural proteins were safe and well tolerated and followed up volunteers for 24 months for safety and immunogenicity, respectively.
Journal ArticleDOI
Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.
Julie E. Ledgerwood,Emily E. Coates,Galina Yamshchikov,Jamie G. Saunders,LaSonji A. Holman,Mary E. Enama,Adam DeZure,Rebecca M. Lynch,Ingelise J. Gordon,Sarah A. Plummer,Cynthia S. Hendel,Amarendra Pegu,Michelle Conan-Cibotti,Sandra Sitar,Robert T. Bailer,Sandeep Narpala,Adrian B. McDermott,Mark K. Louder,Sijy O'Dell,Sankar Mohan,Janardan P. Pandey,Richard M. Schwartz,Zonghui Hu,Richard A. Koup,Edmund V. Capparelli,John R. Mascola,Barney S. Graham +26 more
TL;DR: The human monoclonal antibody VRC01 was well tolerated when delivered i.v. or s.c. and demonstrated expected half‐life and pharmacokinetics for a human immunoglobulin G.mAb, and dosing schedules for planning HIV‐1 prevention efficacy studies are informed.
Journal ArticleDOI
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults.
Martin R. Gaudinski,Emily E. Coates,Katherine V. Houser,Grace L. Chen,Galina Yamshchikov,Jamie G. Saunders,LaSonji A. Holman,Ingelise J. Gordon,Sarah H. Plummer,Cynthia S. Hendel,Michelle Conan-Cibotti,Margarita M. Gomez Lorenzo,Sandra Sitar,Kevin Carlton,Carolyn M. Laurencot,Robert T. Bailer,Sandeep Narpala,Adrian B. McDermott,Aryan M. Namboodiri,Janardan P. Pandey,Richard M. Schwartz,Zonghui Hu,Richard A. Koup,Edmund V. Capparelli,Barney S. Graham,John R. Mascola,Julie E. Ledgerwood +26 more
TL;DR: The human bnMAb VRC01LS was safe and well tolerated when delivered intravenously or subcutaneously and the half-life was more than 4-fold greater when compared to wild-type VRC03, designed for extended serum half- life by increased binding affinity to the neonatal Fc receptor.
Journal ArticleDOI
Safety, tolerability, pharmacokinetics, and immunogenicity of the therapeutic monoclonal antibody mAb114 targeting Ebola virus glycoprotein (VRC 608): an open-label phase 1 study.
Martin R. Gaudinski,Emily E. Coates,Laura Novik,Alicia T. Widge,Katherine V. Houser,Eugeania Burch,LaSonji A. Holman,Ingelise J. Gordon,Grace L. Chen,Cristina Carter,Martha Nason,Sandra Sitar,Galina Yamshchikov,Nina M. Berkowitz,Charla A. Andrews,Sandra Vazquez,Carolyn M. Laurencot,John Misasi,Frank J. Arnold,Kevin Carlton,Heather Lawlor,Jason G. D. Gall,Robert T. Bailer,Adrian B. McDermott,Edmund V. Capparelli,Richard A. Koup,John R. Mascola,Barney S. Graham,Nancy J. Sullivan,Julie E. Ledgerwood,Cynthia S. Hendel,Sarah H. Plummer,Pamela Costner,Jamie G. Saunders,Floreliz Mendoza,Aba Mensima Eshun,Joseph P. Casazza,Abidemi Ola,William Whalen,Xiaolin Wang,Jennifer Cunningham,Olga Vasilenko,Catina R. Boyd,Olga Trofymenko,Maria Burgos Florez,Somia P. Hickman,Ro Shauna S Rothwell,Iris Pittman,Lam Le,Brenda Larkin,Josephine H. Cox,Preeti Apte,Renunda Hicks,Cora Trelles Cartagena,Pernell Williams,LaShawn Requilman,Thuy Nguyen,Colin Tran,Michelle Conan-Cibotti,Judy Stein,Tatiana Beresnev +60 more
TL;DR: mAb114 was well tolerated, showed linear pharmacokinetics, and was easily and rapidly infused, making it an attractive and deployable option for treatment in outbreak settings, and one serious adverse event occurred that was unrelated to mAb114.